 Good evening all, myself Dr. Vinayama Nagarouda, junior resident from Mysore Medical College. My paper is on role of HRCT in RTPCR negative symptomatic patients for COVID-19 pneumonia. Coming to introduction, for the diagnosis of COVID infection, RTPCR test has become a standard because of its insufficient specimen or laboratory error, RTPCR testing results may be falsely negative. HRCT has a higher rate of detection of patients with disease in incubation period, particularly with initial negative RTPCR results. Thus CT is helpful for early diagnosis, timely isolation and treatment of COVID-19 pneumonia. The aim of this study is to know the role of HRCT in those with negative initial RTPCR results with highly suspected SARS-CoV-2 infection. Coming to materials and methods, the study was done for a duration of six months from May 2020 to October 2020. It includes 100 patients and all these patients had symptoms of cough, breathlessness and fever. But on doing RTPCR test, the results were negative. So these type of patients were included in our study and on these patients HRCT thorax was performed with 128 slice single source dual energy MDCT tomography machine in our department. Coming to results, in our study, ground glass opacity and consolidation are the two main HRCT features in RTPCR negative symptomatic patients and is seen among 70 and 32 patients respectively, while combination of ground glassing and consolidation was seen in 42 patients. The lesions were predominantly peripheral or subplural in 42 in 44 patients, both subplural and centroparanchymal location in 45 patients, and only one patient had only centroparanchymal location involvement. Coming to images and tables, in this axial HRCT images, we can see ground glass opacities in the above images. The ground glass opacities are mainly seen in the subplural location and in the lower images, we can see the lesions in both subplural and centroparanchymal location. These are axial and coronal HRCT images. Here we can see ground glass opacities is associated with adjacent consolidation. Coming to distribution of HRCT characteristics, ground glass opacities were seen in 77.7% of patients. Ground glass opacities with consolidation was seen in 46.6% of patients. Only isolated consolidation was seen in 35.5% of patients. Lymphadenopathy was seen in 10% of patients. Coming to location of ground glass opacities, in 45% of cases, the ground glass opacities were seen in both subplural and centroparanchymal location. In 44% of patients, it is seen only in subplural location and in 1% of patients, the ground glass opacities were present only in the centroparanchymal location. Coming to discussion, our study detects 90 cases who had just HRCT features related to COVID-19 pneumonia in 100 symptomatic cases. Thus, HRCT is useful in patients with a suspicious clinical presentation of COVID-19 pneumonia and a negative initial RTPCR test. Ground glass opacities and consolidation were the two main HRCT features in RTPCR negative symptomatic patients of our study. Presence of bilateral multiple subplural ground glass opacities and consolidatory changes are to be considered as COVID-19 pneumonia in this current pandemic, even though the RTPCR results are negative. Ground glass opacities and consolidation are the most common HRCT features in RTPCR positive patients and the most common location is subplural and peripheral and the next most common is the centroparanchymal location. And similarly, in the same way, our study also detects ground glass opacities and consolidation in subplural and centroparanchymal location, similar to that in RTPCR positive cases. So, the presence of ground glass opacities and consolidation in symptomatic patients even though they are RTPCR negative, they should be treated as COVID positive pneumonia as per our case, as per our study. This is the comparison table between various studies on COVID-19 pneumonia. Our study includes only RTPCR negative group and other studies are on RTPCR positive group, but we can find that subplural location, ground glass opacities and consolidation are common in both RTPCR positive and negative groups. This HRCT just can place an important role in detecting COVID-19 pneumonia in those symptomatic patients in whom RTPCR test results are negative. In the context of the current pandemic and multiple genetic mutations of the virus, particularly in those symptomatic patients or those with exposure history, positive HRCT should be regarded as strongly suspicious for COVID-19 pneumonia despite negative RTPCR test results. Recommendations has to be made that patients can be managed with appropriate infection control measures and RTPCR swap testing should be repeated. These are my references. Thank you.